Zoetis Inc. (NYSE:ZTS) Position Lifted by IFM Investors Pty Ltd

IFM Investors Pty Ltd lifted its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 10.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 92,781 shares of the company's stock after buying an additional 8,570 shares during the quarter. IFM Investors Pty Ltd's holdings in Zoetis were worth $15,276,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of Zoetis by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company's stock valued at $6,739,905,000 after acquiring an additional 120,158 shares during the period. Geode Capital Management LLC increased its holdings in shares of Zoetis by 1.8% in the 4th quarter. Geode Capital Management LLC now owns 10,617,897 shares of the company's stock valued at $1,726,075,000 after acquiring an additional 190,137 shares during the period. Polen Capital Management LLC increased its holdings in shares of Zoetis by 17.5% in the 4th quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company's stock valued at $1,219,237,000 after acquiring an additional 1,116,541 shares during the period. Wellington Management Group LLP increased its holdings in shares of Zoetis by 78.5% in the 4th quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company's stock valued at $1,133,755,000 after acquiring an additional 3,059,255 shares during the period. Finally, Northern Trust Corp increased its holdings in shares of Zoetis by 13.3% in the 4th quarter. Northern Trust Corp now owns 6,426,394 shares of the company's stock valued at $1,047,052,000 after acquiring an additional 755,893 shares during the period. Hedge funds and other institutional investors own 92.80% of the company's stock.

Insider Activity

In other news, EVP Roxanne Lagano sold 652 shares of the stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the sale, the executive vice president owned 15,129 shares of the company's stock, valued at $2,571,930. This represents a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is owned by insiders.

Zoetis Price Performance

Shares of NYSE:ZTS traded down $2.04 on Monday, reaching $157.14. 1,544,040 shares of the company were exchanged, compared to its average volume of 2,569,123. The firm has a market cap of $69.96 billion, a price-to-earnings ratio of 28.19, a price-to-earnings-growth ratio of 2.64 and a beta of 0.91. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The company has a 50-day moving average of $161.16 and a 200-day moving average of $162.08. The company has a current ratio of 1.74, a quick ratio of 1.04 and a debt-to-equity ratio of 1.12.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. The business had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The company's quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.38 earnings per share. Equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.27%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis's payout ratio is currently 35.91%.

Analyst Upgrades and Downgrades

ZTS has been the topic of several recent research reports. UBS Group dropped their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and dropped their price objective for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, Piper Sandler boosted their price objective on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Monday, May 12th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $212.13.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.